MX2021005248A - Anticuerpos contra cd73 activadores de células b. - Google Patents

Anticuerpos contra cd73 activadores de células b.

Info

Publication number
MX2021005248A
MX2021005248A MX2021005248A MX2021005248A MX2021005248A MX 2021005248 A MX2021005248 A MX 2021005248A MX 2021005248 A MX2021005248 A MX 2021005248A MX 2021005248 A MX2021005248 A MX 2021005248A MX 2021005248 A MX2021005248 A MX 2021005248A
Authority
MX
Mexico
Prior art keywords
antibodies
cells
cell activating
activating
lymphoid
Prior art date
Application number
MX2021005248A
Other languages
English (en)
Inventor
Andrew Hotson
Emily Piccione Griffin
Joseph Buggy
Original Assignee
Corvus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvus Pharmaceuticals Inc filed Critical Corvus Pharmaceuticals Inc
Publication of MX2021005248A publication Critical patent/MX2021005248A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente descripción se proporcionan, entre otros, métodos y composiciones que usan e incluyen anticuerpos anti-CD73 que pueden activar las células B y afectar la redistribución de las células B desde los tejidos linfoides a los órganos linfoides. Este efecto único y previamente desconocido de los anticuerpos anti-CD73 puede ser útil para el tratamiento de diversas indicaciones, por ejemplo, potenciar la inmunidad para cánceres inmunogénicos, tratar enfermedades autoinmunitarias (por ejemplo, esclerosis múltiple), enfermedades inflamatorias o enfermedades infecciosas.
MX2021005248A 2018-11-05 2019-11-05 Anticuerpos contra cd73 activadores de células b. MX2021005248A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862756065P 2018-11-05 2018-11-05
US201962848524P 2019-05-15 2019-05-15
US201962855601P 2019-05-31 2019-05-31
PCT/US2019/059933 WO2020097127A2 (en) 2018-11-05 2019-11-05 B-cell activating cd73 antibodies

Publications (1)

Publication Number Publication Date
MX2021005248A true MX2021005248A (es) 2021-08-11

Family

ID=70612455

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005248A MX2021005248A (es) 2018-11-05 2019-11-05 Anticuerpos contra cd73 activadores de células b.

Country Status (9)

Country Link
US (1) US20220242963A1 (es)
EP (1) EP3880710A4 (es)
JP (1) JP2022512901A (es)
KR (1) KR20210100099A (es)
AU (1) AU2019377454A1 (es)
CA (1) CA3118706A1 (es)
IL (1) IL282852A (es)
MX (1) MX2021005248A (es)
WO (1) WO2020097127A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021138498A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
BR112022013236A2 (pt) 2020-01-03 2022-09-06 Incyte Corp Anticorpos anti-cd73 e usos dos mesmos
TW202222840A (zh) * 2020-12-11 2022-06-16 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ７３的抗原結合蛋白及其應用
TW202400242A (zh) * 2022-03-14 2024-01-01 大陸商上海華奧泰生物藥業股份有限公司 抗體藥物偶聯物及其應用
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340569B1 (en) * 1997-11-12 2002-01-22 University Of Pittsburgh Monoclonal antibody and antigens specific therefor and methods of using same
WO2017100670A1 (en) * 2015-12-09 2017-06-15 Corvus Pharmaceuticals, Inc. Humanized anti-cd73 antibodies
US10793636B2 (en) * 2016-07-11 2020-10-06 Corvus Pharmaceuticals, Inc. Anti-CD73 antibodies
US20210107989A1 (en) * 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors

Also Published As

Publication number Publication date
US20220242963A1 (en) 2022-08-04
IL282852A (en) 2021-06-30
WO2020097127A2 (en) 2020-05-14
CA3118706A1 (en) 2020-05-14
EP3880710A4 (en) 2022-07-27
AU2019377454A1 (en) 2021-05-27
WO2020097127A3 (en) 2020-06-18
KR20210100099A (ko) 2021-08-13
JP2022512901A (ja) 2022-02-07
EP3880710A2 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
MX2021005248A (es) Anticuerpos contra cd73 activadores de células b.
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
PH12020551317A1 (en) Anti-cd73 antibodies and methods of use thereof
MX2019012233A (es) Anticuerpos anti-sirpa.
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
MA41060A (fr) Compositions comprenant des souches bactériennes
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MA41010A (fr) Compositions comprenant des souches bactériennes
TW201613880A (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
EP4183806A3 (en) Glycan-interacting compounds and methods of use
EA202091219A1 (ru) Культивирование плаценты с целью выделения экзосом
EA202092086A1 (ru) Ингибиторы аргиназы
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
EA202091708A1 (ru) Ингибиторы днк-пк
MX2019015071A (es) Composiciones y metodos para tratar tauopatias.
JO3576B1 (ar) أجسام مضادة لـ tau واستخداماتها
WO2017214170A3 (en) Baff-r antibodies and uses thereof
MX2022002740A (es) Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
PH12018500578A1 (en) Methods of treating inflammatory diseases
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
EA202190094A1 (ru) Антитела против cd40 для применения в лечении аутоиммунного заболевания
EA202192488A1 (ru) Антитела против tsg-6 и их применения
MX2021005245A (es) Composiciones de oligosacaridos y metodos de uso de las mismas.
MX2020013621A (es) Composiciones y metodos de tratamiento de vih.